Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/232960
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Implications of maraviroc and/or rapamycin in a mouse model of fragility |
Autor: | Pérez-Martínez, Laura; Romero, Lourdes; Muñoz-Galván, Sandra CSIC ORCID ; Verdugo-Sivianes, Eva M. CSIC ORCID; Rubio-Mediavilla, Susana; Oteo, José Antonio; Carnero, Amancio CSIC ORCID; Blanco, José Ramón | Fecha de publicación: | 30-abr-2020 | Editor: | Impact Journals | Citación: | Aging 12(9): 8565-8582 (2020) | Resumen: | [Background] As age increases, the risk of developing fragility also increases. Improving the knowledge of frailty could contribute to maintaining the functional ability of elderly people. Interleukin (IL)-10 homozygous knockout mice (IL-10tm/tm [IL10KO]) constitute an excellent tool for the study of frailty. Because patients with frailty demonstrate an overexpression of CCR5, rapamycin (RAPA) and/or maraviroc (MVC), two molecules able to decrease CCR5 expression, were evaluated. [Results] Muscle myostatin was reduced in all the therapeutic groups but the MVC group (p <0.001 for RAPA and MVC-RAPA) and in serum samples (p <0.01 for all the groups). Serum CK levels were also significantly lower in MVC and RAPA groups (p <0.01 in both cases). Lower AST levels were observed in all the therapeutic groups (p <0.05 for all of them). The apoptotic effector caspase-3 was significantly lower in MVC and RAPA groups (p<0.05 in both cases). Combined treatment with MVC-RAPA showed a synergistic increase in p-AKT, p-mTOR and SIRT1 levels. [Conclusions] MVC and RAPA show a protective role in some factors involved in frailty. More studies are needed to prove their clinical applications. [Material and methods] Eighty male homozygous IL10KOs were randomly assigned to one of 4 groups (n= 20): i) IL10KO group (IL10KO); ii) IL10KO receiving MVC in drinking water (MVC group), iii) IL10KO receiving RAPA in drinking water (RAPA group), and finally, iv) MVC-RAPA group that received MVC and RAPA in drinking water. Blood and muscle samples were analysed. Survival analysis, frailty index calculation, and functional assessment were also performed. |
Descripción: | This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. | Versión del editor: | http://dx.doi.org/10.18632/aging.103167 | URI: | http://hdl.handle.net/10261/232960 | DOI: | 10.18632/aging.103167 | Identificadores: | doi: 10.18632/aging.103167 e-issn: 1945-4589 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
maraviroc_andor rapamycin.pdf | 2,12 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
4
checked on 12-abr-2024
SCOPUSTM
Citations
6
checked on 19-abr-2024
WEB OF SCIENCETM
Citations
6
checked on 29-feb-2024
Page view(s)
85
checked on 23-abr-2024
Download(s)
116
checked on 23-abr-2024